Targeted alpha therapy (TAT) using lead-212 (Pb-212)-labeled peptides presents an attractive option for the treatment of metastatic neuroendocrine tumors (NETs). As Pb-203 presents an accurate diagnostic surrogate to Pb-212, imaging with Pb-203-labelled peptides can be an important prerequisite to assess the feasibility of TAT with Pb-212-labelled agents. Here, we present the imaging data of a patient with metastatic NET with Pb-203 VMT-α-NET, a somatostatin receptor targeting agent, and demonstrate the matching distribution of Pb-203 VMT-α-NET with Ga-68 DOTANOC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232724 | PMC |
| http://dx.doi.org/10.4103/ijnm.ijnm_2_23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SPECT/CT imaging of EGFR-positive head and neck squamous cell carcinoma patient-derived xenografts with Pb-PSC-panitumumab in NRG mice.
EJNMMI Radiopharm Chem
November 2024
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada.
Background: The objective of this research was the development and evaluation of Pb-labelled panitumumab (Pb-PSC-panitumumab) as an immuno-SPECT radioligand for the detection of EGFR + head and neck squamous cell carcinoma (HNSCC) in a patient-derived xenograft (PDX) mouse model. The 51.9 h physical half-life and favourable γ-emission (279 keV; 81%) of Pb offer an excellent opportunity for developing immuno-SPECT radioligands.
View Article and Find Full Text PDFLead-203 VMT-α-Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent.
Indian J Nucl Med
May 2024
Department of Nuclear Medicine, Fortis Memorial Research Institute, Gurugram, Haryana, India.
Targeted alpha therapy (TAT) using lead-212 (Pb-212)-labeled peptides presents an attractive option for the treatment of metastatic neuroendocrine tumors (NETs). As Pb-203 presents an accurate diagnostic surrogate to Pb-212, imaging with Pb-203-labelled peptides can be an important prerequisite to assess the feasibility of TAT with Pb-212-labelled agents. Here, we present the imaging data of a patient with metastatic NET with Pb-203 VMT-α-NET, a somatostatin receptor targeting agent, and demonstrate the matching distribution of Pb-203 VMT-α-NET with Ga-68 DOTANOC.
View Article and Find Full Text PDFEcological-health risks assessment and source apportionment of heavy metals in agricultural soils around a super-sized lead-zinc smelter with a long production history, in China.
Environ Pollut
August 2022
Nanjing Institute of Environmental Sciences, Ministry of Ecology and Environment, Nanjing, 210042, China; State Environmental Protection Key Laboratory of Soil Environmental Management and Pollution Control, Nanjing Institute of Environmental Sciences, Ministry of Ecology and Environment, Nanjing, 210042, China. Electronic address:
Smelting activities are considered as the primary cause of heavy metal (HM) accumulation in soils, and the human health around the smelter has been a great concern worldwide. In this study, a total of 242 agricultural soil samples were collected around a large scale Pb/Zn smelter in China, and eight HMs (As, Cd, Cr, Cu, Hg, Ni, Pb and Zn) were analyzed to assess HMs status, ecological -health risks, and identify source. Monte Carlo simulation was utilized to evaluate the probabilistic health risks, and positive matrix factorization (PMF) was employed to identify sources.
View Article and Find Full Text PDFProduction, purification, and radiolabeling of the Pb/Pb theranostic pair.
EJNMMI Radiopharm Chem
February 2021
Life Sciences Division, TRIUMF, Vancouver, BC, Canada.
Background: Lead-212 (Pb, t = 10.6 h) and lead-203 (Pb, t = 51.9 h) are an element-equivalent, or a matched theranostic radioisotope pair that show great potential for application in targeted radionuclide therapy (TRT) and single-photon emission computed tomography (SPECT), respectively.
View Article and Find Full Text PDFPb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer.
Curr Med Chem
February 2021
Viewpoint Molecular Targeting, Inc., Coralville, Iowa 52241, United States.
Receptor-targeted image-guided Radionuclide Therapy (TRT) is increasingly recognized as a promising approach to cancer treatment. In particular, the potential for clinical translation of receptor-targeted alpha-particle therapy is receiving considerable attention as an approach that can improve outcomes for cancer patients. Higher Linear-energy Transfer (LET) of alpha-particles (compared to beta particles) for this purpose results in an increased incidence of double-strand DNA breaks and improved-localized cancer-cell damage.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!